Granted Patent B2

US 12,577,213 · App. 18/252,039 · Granted Mar 17, 2026

Inventors: Gang Liu (Zhejiang, CN); Yao Ma (Zhejiang, CN); Wenjun Yu (Zhejiang, CN)

Assignee: NINGBO COMBIREG PHARMACEUTICAL TECHNOLOGY CO., LTD.

C07D243/14A61P35/00C07B2200/05

Abstract

Claims (166)

1 . A compound represented by formula I or a pharmaceutically acceptable salt thereof,

wherein, X is hydrogen, fluorine, chlorine, bromine or iodine;

R 1a and R 1b are independently hydrogen, deuterium, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—;

R 6 is H, C 1-3 alkyl, C 2-4 alkenyl, C 2-4 alkynyl or deuterated C 1-3 alkyl;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), wherein R 12 , R 17 and R 18 are independently C 1-3 alkyl, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—; R 15 and R 16 are independently H, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 13 and R 14 are independently OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—;

or, R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 ; the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 contains 0-2 heteroatoms selected from N, O or S, besides the 1 N attached to the shown carbonyl;

R 19 is halogen, O═, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 8 , R 9 , R 10 and R 11 are independently hydrogen or deuterium;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 is deuterium or a deuterated group.

2 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound satisfies any one of the following conditions:

(1) X is chlorine or bromine;

(2) R 1a and R 1b are the same;

(3) R 1a and R 1b are independently C 1-3 alkyl or deuterated C 1-3 alkyl;

(4) R 2a , R 2b and R 2c are the same;

(5) R 2a , R 2b and R 2c are independently hydrogen;

(6) any two or three of R 3 , R 4 and R 5 are the same;

(7) R 3 , R 4 and R 5 are independently C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—;

(8) R 6 is H, C 1-3 alkyl, C 2-4 alkynyl or deuterated C 1-3 alkyl;

(9) when R 7 is —OR 12 , R 12 is C 1-3 alkyl or deuterated C 1-3 alkyl;

(10) when R 7 is —NR 13 R 14 , R 13 and R 14 are independently OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—;

(11) when R 7 is —NR 13 R 14 , R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 , R 19 is independently halogen, O═, C 1-3 alkyl or deuterated C 1-3 alkyl;

(12) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 15 and R 16 are independently C 1-3 alkyl;

(13) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 15 and R 16 are the same;

(14) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 17 and R 18 are the same;

(15) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 17 and R 18 are independently C 1-3 alkyl;

(16) R 8 is hydrogen;

(17) R 9 is hydrogen;

(18) R 10 is hydrogen;

(19) R 11 is hydrogen;

(20) R 6 is hydrogen, R 7 is —OR 12 , —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), —NR 13 R 14 ; and (21) at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 and R 7 is deuterium or a deuterated group.

3 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound satisfies any one of the following conditions:

(1) X is bromine;

(2) R 1a and R 1b are independently C 1-3 alkyl;

(3) R 3 , R 4 and R 5 are the same:

(4) R 3 , R 4 and R 5 are independently C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—;

(5) R 6 is H, C 1-3 alkyl or deuterated C 1-3 alkyl;

(6) R 12 is deuterated C 1-3 alkyl;

(7) when R 7 is —NR 13 R 14 , R 13 is OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—; R 14 is C 1-3 alkyl or deuterated C 1-3 alkyl;

(8) when R 7 is —NR 13 R 14 , R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 , the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 contains 0-1 heteroatoms optionally selected from N, O or S, besides the 1 N attached to the shown carbonyl:

(9) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 15 and R 16 are independently methyl;

(10) when R 7 is —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), R 17 and R 18 are independently methyl;

(11) R 19 is independently halogen, O═ or C 1-3 alkyl;

(12) at least one of R 3 , R 4 , R 5 , R 6 and R 7 is deuterium or a deuterated group;

(13) when R 1a and Rib are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl, ethyl, n-propyl or isopropyl;

(14) when R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—, the C 1-3 alkyl in the C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl and deuterated C 1-3 alkyl-O— is methyl, ethyl, n-propyl or isopropyl;

(15) when Re is C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl, ethyl, n-propyl or isopropyl;

(16) when R 6 is C 2-4 alkenyl, the C 2-4 alkenyl is vinyl, 1-propenyl,

(17) when R 6 is C 2-4 alkynyl, the C 2-4 alkynyl is ethynyl or

(18) when R 12 , R 17 and R 18 are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl, ethyl, n-propyl or isopropyl;

(19) when R 15 and R 16 are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl are methyl, ethyl, n-propyl or isopropyl;

(20) when R 13 and R 14 are independently C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—, the C 1-3 alkyl in the C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O— is methyl, ethyl, n-propyl or isopropyl;

(21) when R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4-6-membered aliphatic heterocycle substituted by one or more R 19 , the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 is 4- to 6-membered aliphatic heterocycle, wherein containing 0-1 heteroatoms selected from N, O or S, besides the 1 N attached to the shown carbonyl;

(22) when R 19 is halogen, the halogen is fluorine, chlorine, bromine or iodine; and

(23) when R 19 is C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl, ethyl, n-propyl or isopropyl.

4 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound satisfies any one of the following conditions:

(1) R 1a and R 1b are independently methyl or CD;

(2) R 3 , R 4 and R 5 are independently methyl-O—, CD 3 , —CD 2 -CD 3 or CD 3 -O—;

(3) R 6 is H, methyl or CD 3 ;

(4) R 12 is CD 3 ;

(5) R 13 is OH, methyl, ethyl, CD 3 , —CD 2 -CD 3 or CD 3 -O—, and R 14 is CD 3 or —CD 2 -CD 3 ; or, R 13 and R 14 together with the attached nitrogen atom form:

(7) —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ) is —C(Me) 2 P(═O)(OMe) 2 or —CH 2 —P(═O)(OMe) 2 ;

(8) R 19 is F, O═ or methyl; and

(9) one or two of R 3 , R 4 and R 5 ; R 6 ; and R 7 are deuterium or a deuterated group.

5 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound satisfies any one of the following conditions:

6 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound represented by formula I is of the following Scheme 1, Scheme 2, Scheme 4, Scheme 4, Scheme 5, or Scheme 6;

Scheme 1,

wherein, X is chlorine or bromine;

R 1a and R 1b are independently C 1-3 alkyl or deuterated C 1-3 alkyl;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—;

R 6 is H, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 );

R 12 is deuterated C 1-3 alkyl;

R 15 and R 16 are independently C 1-3 alkyl;

R 17 and R 18 are independently C 1-3 alkyl;

R 13 is OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—;

R 14 is C 1-3 alkyl or deuterated C 1-3 alkyl;

or, R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 ;

R 19 is halogen, O═, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 8 , R 9 , R 10 and R 11 are hydrogen;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 and R 7 is deuterium or a deuterated group;

Scheme 2,

wherein, X is chlorine or bromine;

R 1a and R 1b are independently C 1-3 alkyl; and R 1a and R 1b are the same;

R 2a , R 2b and R 2c are independently hydrogen; and R 2a , R 2b and R 2c are the same;

R 3 , R 4 and R 5 are independently C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—; and R 3 , R 4 and R 5 are the same;

R 6 is H; R 7 is —OR 12 , —NR 13 R 14 , or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ); wherein R 12 is independently deuterated C 1-3 alkyl; R 15 and R 16 are independently C 1-3 alkyl; R 17 and R 18 are independently C 1-3 alkyl; R 13 is methyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—; R 14 is methyl or deuterated C 1-3 alkyl; or, R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 ; R 15 , R 16 , R 17 and R 18 are independently C 1-3 alkyl; R 19 is halogen;

or, R 6 is C 1-3 alkyl; R 7 is —NR 13 R 14 , R 13 is OH, C 1-3 alkyl, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—; R 14 is C 1-3 alkyl or deuterated C 1-3 alkyl;

R 8 , R 9 , R 10 and R 11 are hydrogen;

wherein, at least one of R 3 , R 4 , R 5 , R 6 and R 7 is deuterium or a deuterated group;

Scheme 3,

X is hydrogen, fluorine, chlorine, bromine or iodine;

R 1a and R 1b are independently C 1-3 alkyl or deuterated C 1-3 alkyl;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—;

R 6 is H, C 1-3 alkyl, C 2-4 alkynyl or deuterated C 1-3 alkyl;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), wherein R 12 , R 17 and R 18 are independently C 1-3 alkyl or deuterated C 1-3 alkyl; R 15 and R 16 are independently H, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 13 and R 14 are independently OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—; or, R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 ; R 19 is halogen, O═, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 8 , R 9 , R 10 and R 11 are independently hydrogen or deuterium;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 is deuterium or a deuterated group;

Scheme 4,

X is hydrogen, fluorine, chlorine, bromine or iodine;

R 1a and R 1b are independently C 1-3 alkyl or deuterated C 1-3 alkyl;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—;

R 6 is H, C 1-3 alkyl,

 or deuterated C 1-3 alkyl;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), wherein R 12 , R 17 and R 18 are independently C 1-3 alkyl or deuterated C 1-3 alkyl; R 15 and R 16 are independently H, C 1-3 alkyl or deuterated C 1-3 alkyl;

R 13 and R 14 are independently OH, C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—; or, R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 ;

R 8 , R 9 , R 10 and R 11 are independently hydrogen or deuterium;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 is deuterium or a deuterated group;

Scheme 5,

X is fluorine, chlorine or bromine;

R 1a and R 1b are independently methyl or deuterated methyl;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently methyl, methyl-O—, CD 3 or CD 3 -O—;

R 6 is H, methyl,

 or CD 3 ;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), wherein R 12 , R 17 and R 18 are independently methyl, ethyl, CD 3 or —CD 2 -CD 3 ;

R 15 and R 16 are independently methyl, ethyl, CD 3 or —CD 2 -CD 3 ;

R 13 and R 14 are independently OH, methyl, ethyl, CD 3 , —CD 2 -CD 3 or CD 3 -O—, or, R 13 and R 14 together with the attached nitrogen atom form:

R 8 , R 9 , R 10 and R 11 are independently hydrogen or deuterium;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 is deuterium or a deuterated group; or

Scheme 6,

X is chlorine or bromine;

R 1a and R 1b are independently methyl or CD 3 ;

R 2a , R 2b and R 2c are independently hydrogen or deuterium;

R 3 , R 4 and R 5 are independently methyl, methyl-O—, CD 3 or CD 3 -O—;

R 6 is H, methyl, or CD 3 ;

R 7 is —OR 12 , —NR 13 R 14 or —C(R 15 R 16 )—P(═O)(OR 17 OR 18 ), wherein R 12 , R 17 and R 18 are independently methyl, ethyl, CD 3 or —CD 2 -CD 3 ;

R 15 and R 16 are independently methyl;

R 13 and R 14 are independently methyl, ethyl, methyl-O—, CD 3 , —CD 2 -CD 3 or CD 3 -O—;

or, R 13 and R 14 together with the attached nitrogen atom form:

R 8 , R 9 , R 10 and R 11 are independently hydrogen or deuterium;

wherein, at least one of R 1a , R 1b , R 3 , R 4 , R 5 , R 6 and R 7 is deuterium or a deuterated group.

7 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound represented by formula I or the pharmaceutically acceptable salt thereof is selected from the following compounds,

8 . A pharmaceutical composition, which comprises the compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier, wherein the dosage of the compound represented by formula I or the pharmaceutically acceptable salt thereof is a therapeutically effective amount.

9 . A method for treating a proliferative disease, comprising:

administering the compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.

10 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 3 , wherein, the compound satisfies any one of the following conditions:

(1) when R 1a and R 1b are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl;

(2) when R 3 , R 4 and R 5 are independently C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl or deuterated C 1-3 alkyl-O—, the C 1-3 alkyl in the C 1-3 alkyl, C 1-3 alkyl-O—, deuterated C 1-3 alkyl and deuterated C 1-3 alkyl-O— is methyl;

(3) when Re is C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl;

(4) when R 12 , R 17 and R 18 are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl;

(5) when R 15 and R 16 are independently C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl are methyl or ethyl;

(6) when R 13 and R 14 are independently C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O—, the C 1-3 alkyl in the C 1-3 alkyl, deuterated C 1-3 alkyl, C 1-3 alkyl-O— or deuterated C 1-3 alkyl-O— is methyl or ethyl;

(7) when R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4-6-membered aliphatic heterocycle substituted by one or more R 19 , the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 is 6-membered heterocyclic alkyl, wherein containing 0-1 heteroatoms selected from N, O or S, besides the 1 N attached to the shown carbonyl;

(8) when R 19 is halogen, the halogen is fluorine or chlorine; and

(9) when R 19 is C 1-3 alkyl or deuterated C 1-3 alkyl, the C 1-3 alkyl in the C 1-3 alkyl and the deuterated C 1-3 alkyl is methyl.

11 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 3 , wherein, the compound satisfies any one of the following conditions:

(1) when R 19 is halogen, the halogen is fluorine; and

(2) when R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4-6-membered aliphatic heterocycle substituted by one or more R 19 , the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 is 4- to 6-membered heterocyclic alkyl, wherein containing 0-1 heteroatoms selected from N, O or S, besides the 1 N attached to the shown carbonyl; the 4- to 6-membered heterocyclic alkyl is

12 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 10 , wherein,

when R 13 and R 14 together with the attached nitrogen atom form: a 4- to 6-membered aliphatic heterocycle or a 4-6-membered aliphatic heterocycle substituted by one or more R 19 , the 4- to 6-membered aliphatic heterocycle in the 4- to 6-membered aliphatic heterocycle and the 4- to 6-membered aliphatic heterocycle substituted by one or more R 19 is 6-membered heterocyclic alkyl; the 6-membered heterocyclic alkyl is

13 . The compound represented by formula I or the pharmaceutically acceptable salt thereof according to claim 6 , wherein,

in Scheme 6, R 12 , R 17 and R 18 are independently methyl or CD 3 .

14 . The method according to claim 9 , wherein, the proliferative disease is selected from cancer, lymphatic hematopoietic system tumor, marrow hematopoietic system tumor, interstitial tumor, teratoma, and glioma.

15 . The method according to claim 14 , wherein, the method satisfies any one of the following conditions:

(1) the cancer is selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, renal cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, adrenal cancer, prostate cancer, stomach cancer, vaginal cancer, cervical cancer, endometrial cancer, central nervous system tumor, melanoma, seminoma, neuroblastoma, leukemia, thyroid cancer and skin cancer;

(2) the lymphatic hematopoietic system tumor is selected from acute lymphoblastic leukemia, B-cell lymphoma and Burketts lymphoma;

(3) the marrow hematopoietic system tumor is selected from acute and chronic myeloid leukemia and promyelocytic leukemia; and

(4) the interstitial tumor is selected from fibrosarcoma and rhabdomyosarcoma.

16 . The method according to claim 15 , wherein a cell of the lung cancer is A549 non-small cell lung cancer cell; a cell of the colon cancer is HCT116 colon cancer cell; a cell of the central nervous system tumor is SF295 central nervous system tumor cell; a cell of the melanoma is LOX-IMVI melanoma cell; a cell of the renal cancer is 786-0 renal cancer cell; a cell of the leukemia is K562 leukemia cell; a cell of the prostate cancer is PC-3 prostate cancer cell; a cell of the ovarian cancer is OVCAR-3 ovarian cancer cell; a cell of the breast cancer is HS 578T breast cancer cell.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (16)